Sutro Biopharma Inc (STRO)

$2.01 +0.16 (8.65%)
Market Cap 152.55M
Revenue (ttm) 153.73M
Net Income (ttm) -106.79M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -69.47%
Debt to Equity Ratio 0.00
Volume 1,311,800
Avg Vol 1,090,808
Day's Range N/A - N/A
Shares Out 82.46M
Stochastic %K 38%
Beta 1.15
Analysts Strong Sell
Price Target $11.50

Latest News on STRO

Sutro Biopharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 7, 2025, 4:05 PM EST - 10 days ago

Sutro Biopharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Sutro Biopharma: I Don't Buy That Their Pipeline Is Worthless

Jan 2, 2025, 6:28 PM EST - 15 days ago

Sutro Biopharma: I Don't Buy That Their Pipeline Is Worthless

Sutro Biopharma Reports Third Quarter 2024 Financial Results and Business Highlights

Nov 13, 2024, 4:30 PM EST - 2 months ago

Sutro Biopharma Reports Third Quarter 2024 Financial Results and Business Highlights

Sutro Biopharma Demonstrates Meaningful ADC Innovation with Five Presentations at the 15th Annual World ADC Conference

Nov 4, 2024, 4:05 PM EST - 2 months ago

Sutro Biopharma Demonstrates Meaningful ADC Innovation with Five Presentations at the 15th Annual World ADC Conference

Sutro Biopharma Announces Initiation of the Registration-enabling REFRαME-P1 Trial with Luvelta for Pediatric Patients with CBF/GLIS AML

Nov 1, 2024, 8:00 AM EDT - 2 months ago

Sutro Biopharma Announces Initiation of the Registration-enabling REFRαME-P1 Trial with Luvelta for Pediatric Patients with CBF/GLIS AML

Sutro Biopharma Highlights Next-Generation ADC Innovation and Near-term Pipeline at Research Forum

Oct 10, 2024, 4:05 PM EDT - 3 months ago

Sutro Biopharma Highlights Next-Generation ADC Innovation and Near-term Pipeline at Research Forum

Sutro Biopharma's Competitive ADCs Position It For Future Growth In Oncology

Sep 23, 2024, 12:46 PM EDT - 4 months ago

Sutro Biopharma's Competitive ADCs Position It For Future Growth In Oncology

Sutro Biopharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Sep 20, 2024, 4:01 PM EDT - 4 months ago

Sutro Biopharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Sutro Biopharma Announces Updated Data from Phase 1b Study of Luvelta in Combination with Bevacizumab at ESMO 2024

Sep 14, 2024, 3:00 AM EDT - 4 months ago

Sutro Biopharma Announces Updated Data from Phase 1b Study of Luvelta in Combination with Bevacizumab at ESMO 2024

Sutro Biopharma to Host Research Forum Highlighting Next-Generation ADC Innovation and Near-term Pipeline, on October 10, 2024

Sep 11, 2024, 8:00 AM EDT - 4 months ago

Sutro Biopharma to Host Research Forum Highlighting Next-Generation ADC Innovation and Near-term Pipeline, on October 10, 2024

Sutro Biopharma Announces Initiation of REFRαME-L1 Phase 2 Trial with Luvelta for Patients with Non-Small Cell Lung Cancer

Aug 22, 2024, 8:00 AM EDT - 5 months ago

Sutro Biopharma Announces Initiation of REFRαME-L1 Phase 2 Trial with Luvelta for Patients with Non-Small Cell Lung Cancer

Sutro Biopharma Reports Second Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones

Aug 13, 2024, 4:30 PM EDT - 5 months ago

Sutro Biopharma Reports Second Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones

VGXI Inc. announces a strategic partnership with Sutro Biopharma Inc. to support growing clinical pipeline

Jun 3, 2024, 10:00 AM EDT - 8 months ago

VGXI Inc. announces a strategic partnership with Sutro Biopharma Inc. to support growing clinical pipeline

Sutro Biopharma Reports First Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones

May 13, 2024, 4:30 PM EDT - 8 months ago

Sutro Biopharma Reports First Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones

Sutro Biopharma Announces Initiation of Randomized Portion (Part 2) of REFRαME-O1 Trial

Apr 30, 2024, 8:00 AM EDT - 9 months ago

Sutro Biopharma Announces Initiation of Randomized Portion (Part 2) of REFRαME-O1 Trial

Ipsen And Sutro Partnering On ADCs Is A Deal Offering Opportunities For Investors

Apr 5, 2024, 6:31 PM EDT - 10 months ago

Ipsen And Sutro Partnering On ADCs Is A Deal Offering Opportunities For Investors

Sutro Biopharma Announces Pricing of $75 Million Underwritten Offering

Apr 2, 2024, 6:18 AM EDT - 10 months ago

Sutro Biopharma Announces Pricing of $75 Million Underwritten Offering

Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors

Apr 2, 2024, 1:00 AM EDT - 10 months ago

Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors

Sutro Biopharma Reports Full Year 2023 Financial Results, Business Highlights and Select Anticipated Milestones

Mar 25, 2024, 4:30 PM EDT - 10 months ago

Sutro Biopharma Reports Full Year 2023 Financial Results, Business Highlights and Select Anticipated Milestones

Sutro Biopharma to Participate in Upcoming Investor Conferences

Feb 6, 2024, 4:05 PM EST - 1 year ago

Sutro Biopharma to Participate in Upcoming Investor Conferences

Sutro Biopharma Highlights Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeting ADC

Jan 4, 2024, 4:05 PM EST - 1 year ago

Sutro Biopharma Highlights Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeting ADC

Sutro: Luveltamab Data At ESMO Signifies Continued ADC Advancement

Dec 29, 2023, 4:11 PM EST - 1 year ago

Sutro: Luveltamab Data At ESMO Signifies Continued ADC Advancement

Sutro Biopharma to Host Investor Webcast Highlighting Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeted ADC, on January 4, 2024

Dec 14, 2023, 4:05 PM EST - 1 year ago

Sutro Biopharma to Host Investor Webcast Highlighting Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeted ADC, on January 4, 2024

Sutro Biopharma Announces New Positive Data from the Compassionate Use of Luveltamab Tazevibulin (luvelta) in Pediatric Patients with Relapsed/Refractory CBF/GLIS Presented at ASH 2023

Dec 11, 2023, 4:05 PM EST - 1 year ago

Sutro Biopharma Announces New Positive Data from the Compassionate Use of Luveltamab Tazevibulin (luvelta) in Pediatric Patients with Relapsed/Refractory CBF/GLIS Presented at ASH 2023

Sutro Biopharma to Participate in the JMP Securities Hematology and Oncology Summit

Dec 4, 2023, 4:05 PM EST - 1 year ago

Sutro Biopharma to Participate in the JMP Securities Hematology and Oncology Summit

Sutro Biopharma Promotes Jane Chung to President and Chief Operating Officer

Nov 21, 2023, 4:05 PM EST - 1 year ago

Sutro Biopharma Promotes Jane Chung to President and Chief Operating Officer

Sutro Biopharma Reports Third Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones

Nov 13, 2023, 4:30 PM EST - 1 year ago

Sutro Biopharma Reports Third Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones

Sutro Biopharma Announces Presentation of Data for Luveltamab Tazevibulin (luvelta) from the Phase 1 Dose-Expansion Study in Endometrial Cancers at ESMO 2023

Oct 22, 2023, 4:25 AM EDT - 1 year ago

Sutro Biopharma Announces Presentation of Data for Luveltamab Tazevibulin (luvelta) from the Phase 1 Dose-Expansion Study in Endometrial Cancers at ESMO 2023

Sutro Demonstrates Meaningful ADC Innovation with Five Presentations and One Poster at the 14th Annual World ADC Conference

Oct 16, 2023, 4:05 PM EDT - 1 year ago

Sutro Demonstrates Meaningful ADC Innovation with Five Presentations and One Poster at the 14th Annual World ADC Conference

Sutro Biopharma: Luvelta Data For Endometrial Cancer Treatment Approaching

Oct 9, 2023, 9:48 AM EDT - 1 year ago

Sutro Biopharma: Luvelta Data For Endometrial Cancer Treatment Approaching

Sutro Biopharma Appoints Dr. Hans-Peter Gerber as Chief Scientific Officer

Sep 19, 2023, 8:00 AM EDT - 1 year ago

Sutro Biopharma Appoints Dr. Hans-Peter Gerber as Chief Scientific Officer

Sutro BioPharma: Good Stewardship Through Early Trials

Sep 14, 2023, 1:21 PM EDT - 1 year ago

Sutro BioPharma: Good Stewardship Through Early Trials

Sutro Biopharma Reports Second Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones

Aug 10, 2023, 4:30 PM EDT - 1 year ago

Sutro Biopharma Reports Second Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones

Sutro Biopharma and Blackstone Announce Royalty Financing Collaboration

Jun 26, 2023, 8:00 AM EDT - 1 year ago

Sutro Biopharma and Blackstone Announce Royalty Financing Collaboration

Sutro Biopharma Announces Oral Presentation at ASCO 2023 Featuring Data for Luveltamab Tazevibulin from the Phase 1 Dose-Expansion Study in Ovarian Cancer and the Initiation of the Phase 2/3 Pivotal Study REFRaME-O1

Jun 3, 2023, 4:00 PM EDT - 1 year ago

Sutro Biopharma Announces Oral Presentation at ASCO 2023 Featuring Data for Luveltamab Tazevibulin from the Phase 1 Dose-Expansion Study in Ovarian Cancer and the Initiation of the Phase 2/3 Pivotal Study REFRaME-O1

Sutro Biopharma to Participate in the Jefferies Healthcare Conference

May 31, 2023, 8:00 AM EDT - 1 year ago

Sutro Biopharma to Participate in the Jefferies Healthcare Conference

Sutro Biopharma Reports First Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones

May 15, 2023, 8:00 AM EDT - 1 year ago

Sutro Biopharma Reports First Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones

Sutro Biopharma to Present at the JMP Securities Life Sciences Conference

May 8, 2023, 8:00 AM EDT - 1 year ago

Sutro Biopharma to Present at the JMP Securities Life Sciences Conference

Sutro Biopharma Announces the Departure of President of Research & Chief Scientific Officer

Apr 27, 2023, 4:30 PM EDT - 1 year ago

Sutro Biopharma Announces the Departure of President of Research & Chief Scientific Officer

Sutro Biopharma Presents Preclinical Data for its ROR1 Targeting Antibody Drug Conjugate STRO-003 at the AACR Annual Meeting 2023

Apr 18, 2023, 1:30 PM EDT - 1 year ago

Sutro Biopharma Presents Preclinical Data for its ROR1 Targeting Antibody Drug Conjugate STRO-003 at the AACR Annual Meeting 2023

Sutro: Too Little, Too Late For STRO-002, But Platform Is Interesting

Apr 11, 2023, 1:17 PM EDT - 1 year ago

Sutro: Too Little, Too Late For STRO-002, But Platform Is Interesting

Sutro Biopharma Reports Full Year 2022 Financial Results, Business Highlights and Select Anticipated Milestones

Mar 30, 2023, 4:30 PM EDT - 1 year ago

Sutro Biopharma Reports Full Year 2022 Financial Results, Business Highlights and Select Anticipated Milestones

Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 17, 2023, 4:01 PM EDT - 2 years ago

Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sutro Biopharma to Present at the Cowen 43rd Annual Health Care Conference

Mar 1, 2023, 8:00 AM EST - 2 years ago

Sutro Biopharma to Present at the Cowen 43rd Annual Health Care Conference

Sutro Biopharma Appoints Dr. Anne Borgman as Chief Medical Officer

Feb 28, 2023, 8:00 AM EST - 2 years ago

Sutro Biopharma Appoints Dr. Anne Borgman as Chief Medical Officer

Sutro Biopharma Announces Update from STRO-002, Luveltamab Tazevibulin (Luvelta), Phase 1 Dose-Expansion Study and Registrational Plans in Advanced Ovarian Cancer

Jan 9, 2023, 4:05 PM EST - 2 years ago

Sutro Biopharma Announces Update from STRO-002, Luveltamab Tazevibulin (Luvelta), Phase 1 Dose-Expansion Study and Registrational Plans in Advanced Ovarian Cancer

Sutro Biopharma to Present at the 41st Annual J.P. Morgan Healthcare Conference

Jan 4, 2023, 8:00 AM EST - 2 years ago

Sutro Biopharma to Present at the 41st Annual J.P. Morgan Healthcare Conference

Sutro Biopharma to Provide Data Update on STRO-002 and Plans for Registrational Path Forward in Advanced Ovarian Cancer

Dec 21, 2022, 8:00 AM EST - 2 years ago

Sutro Biopharma to Provide Data Update on STRO-002 and Plans for Registrational Path Forward in Advanced Ovarian Cancer

Sutro Biopharma and Vaxcyte Enter into Option Grant Agreement for the Development and Manufacturing Rights of Cell-Free Extract

Dec 20, 2022, 4:05 PM EST - 2 years ago

Sutro Biopharma and Vaxcyte Enter into Option Grant Agreement for the Development and Manufacturing Rights of Cell-Free Extract

Sutro Biopharma Announces Presentation of STRO-002 Data from the Compassionate Use Program in Pediatric Patients with Relapsed/Refractory CBF/GLIS AML at ASH 2022

Dec 10, 2022, 10:30 AM EST - 2 years ago

Sutro Biopharma Announces Presentation of STRO-002 Data from the Compassionate Use Program in Pediatric Patients with Relapsed/Refractory CBF/GLIS AML at ASH 2022